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Abstract Hormone replacement therapy (HRT) use
declined sharply after mid-2002, when the Women’s Health
Initiative trial reported an association between breast cancer
occurrence and HRT. Hypothesized mechanism behind this
association is that HRT promotes growth of pre-existing
small tumors, leading to earlier tumor detection. We eval-
uated the impact of the sudden decline in HRT use on age
distribution of breast cancer in Geneva. We included all
incident breast cancer cases recorded from 1975 to 2006 at
the Geneva cancer registry. We calculated mean annual
incidence rates per 100,000 for 2 year periods for three age
groups and assessed temporal changes by joinpoint
regression. We compared age-specific incidence curves for
different periods, reflecting different prevalence rates of
HRT use. After increasing constantly between 1986 and
2002 among women aged 50–69 years [annual percent
change (APC): ?4.4, P \ 0.0001], rates declined sharply
after 2003 (APC: -6.0; P = 0.0264). Age-specific breast
cancer rates changed dramatically with changes in preva-
lence of HRT use. During low HRT prevalence, breast
cancer incidence increased progressively with age, when
HRT prevalence was reaching its maximum (1995–2002),
higher rates were seen in 60- to 64-year-old women, with a
concomitant decrease in risk among elderly. After the
sudden decline in HRT use, the incidence peak diminished
significantly and incidence increased again with age. Fol-
lowing the abrupt decline in HRT use in Geneva, breast
cancer incidence rates among post-menopausal women
decreased considerably with striking changes in age-spe-
cific incidence rates before, during and after the peak in
HRT prevalence.
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Introduction
After that the Women’s Health Initiative (WHI) random-
ized controlled trial in 2002 reported an increased breast
cancer risk among women using hormone replacement
therapy (HRT) [1, 2], HRT use and breast cancer incidence
among post-menopausal women showed an important
decline in several countries, including USA, Belgium,
France, Australia, United Kingdom, and Germany [3–7].
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In Geneva, Switzerland, breast cancer incidence rates are
among the highest in Europe, and so is the prevalence of
HRT use (46% of women were current users in 2000–2002)
[8, 9]. Following the publication of the WHI and the results
of the Million Women Study in 2003, the use of HRT
among post-menopausal women declined abruptly in Gen-
eva to 31% [8], while mammography screening continued
to expand [10–12].
The biologic mechanism proposed to explain HRT
influence on breast cancer risk is that HRT acts as promoter
of already existing tumor cells [13] leading to an advance
in the presentation of these cancers. We have previously
reported on the change in breast cancer age-specific curve
in Geneva, with the appearance of a peak of incidence
among women aged 60–64 years and a subsequent decline
in the rates of older women. Our hypothesis for such
change was the increasing prevalence of use of HRT during
the 1990s [12].
The present study reports changes in breast cancer
incidence and age distribution following the decrease in the
HRT use among the female population of Geneva. This
report also presents, for the first time, the effect of change
on the age distribution curve.
Materials and methods
We used data from the Geneva cancer registry, which
records information on all incident cancer cases that occur
in the canton (*450,000 inhabitants). Registration is based
on public and private sources of information and is very
accurate, as attested by the low percentage (\2%) of cases
recorded from death certificates only [14].
We considered all incident breast cancer cases diag-
nosed from 1976 to 2006. We calculated the mean annual
incidence rates per 100,000 women for 2 year periods for
three age groups: 25–49 years (pre-menopausal), 50–69
years (early post-menopausal), and C70 years (late post-
menopausal). We assessed trends in age-specific incidence
rates using joinpoint regression. This procedure fits a
model based on a minimum number of joinpoints that are
the points where statistically significant changes in inci-
dence rates occur. Joinpoint regression assumes a log-lin-
ear model, starts with a model with zero joinpoints and
adds more joinpoints, up to three, until the new model has a
statistically significant difference compared to the previous
one. The generation of models and the test of significance
were performed using the Monte Carlo Permutation
method program (version 3.0) [15].
We applied the difference in breast cancer incidence of
women aged 50–69 years between 2005–2006 and 2002–
2003 to women of the same age group resident in the
canton in order to estimate the ‘‘deficit’’ of breast cancer
patients in the period following the decline in HRT use
(2003–2006).
To illustrate the changes in the age incidence curve by
period, we calculated age-specific incidence rates by 5 year
groups for four different periods (1975–1989; 1995–1999;
2001–2003; and 2005–2006).
Results
Trends of incidence rates by age group
Overall, breast cancer incidence rates progressively increased
between 1975 and 2004, and then decreased in 2005–2006 to
levels observed in 1997–1998 (Fig. 1). The overall annual
percent change (APC) was 1.7% (P \ 0.0001; Table 1).
Among women aged 50–69 years, breast cancer incidence
rates were stable from 1975 to 1986, increased sharply until
2001–2002, and then suddenly decreased in 2003–2004
(Fig. 1). In this group, the APC was ?4.4% between 1986
and 2002 (P \ 0.0001), while between 2002 and 2006
the incidence rates decreased 6.0% yearly (P = 0.0264;
Table 1). In contrast, in the age group C 70 years, rates were
relatively constant for the whole period, with a non-signifi-
cant APC of -0.03%. In the age group \ 50 years, breast
cancer rates were relatively constant until 2003–2004, and
then started to increase (APC: ?0.9, P = 0.0012; Fig. 1;
Table 1).
Among women aged 50–69 years, the mean annual
incidence rates were 430.7/100,000 in 2001–2002 and only
341.4/100,000 in 2005–2006, respectively.
Applying this incidence rate difference to the resident
population of the same age group, we estimated a ‘‘deficit’’
of 45 new breast cancer cases per year among post-men-
opausal women aged 50–69 year, representing 21% of
annual cases in this age group and 11% of all breast cancer
cases in Geneva.
Age-specific incidence rates
Figure 2 gives the age-specific breast cancer incidence
rates according to period. For the period 1975–1989, breast
cancer incidence progressively increased with age with the
typical slope down around 50 years (Clemmensen’s hook).
In the period after 1995, an incidence peak gradually
appeared around the age of 60–64 years, while the inci-
dence for older women moved down. This last pattern was
most evident in 2001–2003 when the rate among 60- to
64-year-old women culminated. In 2005–2006, the curve
changed shape again, with a reversal of the peak of inci-
dence rates among women aged 60–64 years, accompanied
by an increase in breast cancer rates among older women.
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Fig. 1 Breast cancer incidence
rates by 2 year periods
according to age-groups.
Geneva 1975–2006
Table 1 Trends of age-adjusted breast cancer incidence rates
25–49 years old 50–69 years old 70? years old All ages
Period APC P value Period APC P value Period APC P value Period APC P value
1975–2006 ?0.9 0.0012 1975–1986 -0.2 0.7643 1975–2006 -0.03 0.8846 1975–2006 ?1.7 0.0001
1986–2002 ?4.4 0.0001
2002–2006 -6.0 0.0264
Geneva 1975–2006
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Fig. 2 Invasive breast cancer
incidence rates by age and
period, Geneva 1975–2006
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Discussion
Following the abrupt decline of HRT use in the canton in
2003, we observed an important decrease in breast cancer
incidence rates and an impressive change of the shape of the
age-specific incidence curve. The incidence rates of early
post-menopausal women decreased by 6% per year from
2002, similar to observations made in USA, Germany, and
Australia [3–5].
Previously, we reported that the age-specific breast can-
cer incidence curve in Geneva peaked around 60–64 years,
was limited to estrogen positive tumors and women who
used HRT independently of their use of mammography
screening [12]. Furthermore, we underlined the inexistence
of such change in the Netherlands, where use of mam-
mography is very high and HRT use very low (only 13%)
[10]. The current study shows, for the first time, a reversal of
this incidence peak, as well as a new increase in older
women. The reversion to previous traditional age incidence
curve and the decline in breast cancer incidence limited to
early post-menopausal women further supports the causal
link between HRT and change in breast cancer incidence.
The mechanism behind the effect of HRT on breast
cancer risk is not fully understood. The hypothesis is that
HRT acts as a ‘fertilizer’ on pre-existing small breast
tumors, meaning that only women who already have latent
breast cancers will develop overt disease when using HRT
[13]. Arguments in favor of this hypothesis are the very
short delay between use of HRT and individual increased
risk of breast cancer, change in HRT use and change in
incidence rates and the fact that the excess concerns mainly
estrogen positive breast cancers, which are more reactive to
hormonal changes [16].
Only few data is currently available on the impact of the
decline of HRT use on the histological type of breast cancer.
The association with HRT use is stronger for lobular car-
cinoma than for ductal carcinoma [17, 18]. In Belgium,
Vankrunkelsven et al. [7] found a larger decline in invasive
lobular than in ductal carcinomas, while inverse results
were found in the USA [19]. For Geneva, we previously
reported a disproportionate increase in lobular cancer inci-
dence during the period 1976–1999. This was particularly
relevant among women aged 50–59 years, born after 1944
[20]. However, in the present analysis, we observed no
decline of incidence of lobular cancer overall or in early
post-menopausal women (data not shown).
Although we are aware that causality cannot be estab-
lished by this kind of descriptive study, alternative expla-
nations of such epidemiologic pattern seem unlikely.
Screening rates have slowly increased in Geneva during
the last years [11]. Sudden changes in lifestyle or environ-
mental risk factors have not been documented and would
not in any case explain such a strong and rapid change.
Conversely, a reduction of exposure to HRT, especially
among those highly hormone sensitive tumors, would stop or
slow their growth, leading to a diagnosis at a later age [21].
In conclusion, we found that in Geneva, breast cancer
incidence rates decreased considerably following the abrupt
reduction in HRT use and that this decline was limited to
post-menopausal women. Age-specific incidence curves
showed completely different patterns before, during, and
after the decrease in the HRT use. If the role of HRT is
limited to fertilization of existing tumors, we could expect a
new increase in cases among older women and a return to
the traditional incidence curve by age in the years to come.
This study demonstrates how use of HRT can dramati-
cally change the natural history of breast cancer.
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